Regeneron Pharmaceuticals' Cost of Revenue fell 247.86% to $318.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 492.04%. This contributed to the annual value of $1.1 billion for FY2025, which is 492.04% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Cost of Revenue stood at $318.7 million for Q4 2025, which was down 247.86% from $281.0 million recorded in Q3 2025.
Regeneron Pharmaceuticals' 5-year Cost of Revenue high stood at $811.7 million for Q4 2021, and its period low was $149.2 million during Q2 2022.
Moreover, its 5-year median value for Cost of Revenue was $258.2 million (2023), whereas its average is $287.8 million.
In the last 5 years, Regeneron Pharmaceuticals' Cost of Revenue soared by 36783.86% in 2021 and then crashed by 7233.96% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Cost of Revenue (Quarter) stood at $811.7 million in 2021, then plummeted by 65.75% to $278.0 million in 2022, then dropped by 6.98% to $258.6 million in 2023, then increased by 26.37% to $326.8 million in 2024, then fell by 2.48% to $318.7 million in 2025.
Its last three reported values are $318.7 million in Q4 2025, $281.0 million for Q3 2025, and $275.6 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value